The first targeted therapy to treat pain crises in people with sickle cell disease, which was recently approved by the FDA, presents a “welcome” new option that payers likely will embrace, a PBM head tells AIS Health. While the drug’s manufacturer cites “positive” early discussions with payers on it, some experts note the lifetime treatment — via a monthly intravenous infusion — is costly: around $100,000 annually.
To access this post, you must purchase a subscription plan. Click Here to purchase.

Already a member? Click Here to login.